A Phase I study of oxaliplatin in cancer patients with impaired renal function
Li Liu, MD
University of Pennsylvania Cancer
Last Modified: May 13, 2001
Presenter: M.A. Graham Affiliation: University of Texas Health Science Center, San Antonio
Oxaliplatin is a new platinum derivative with activity in several solid tumors, especially in some cisplatin/carboplatin-refractory neoplasms. Oxaliplatin clinical toxicity is also distinct from other platinum drugs: it has minimal renal toxicity and hematotoxicity. Therefore, oxaliplatin has been used in patients with impaired renal function. This study was designed to determine the recommended dose of Oxaliplatin in patients with renal dysfunction.
Materials and Methods:
A total of 32 patients were included in this phase I study
Dose escalation from 60-130 mg/m2 in three week cycles.
The patients were grouped according to their 24 hour creatinine clearance (CrCl)
Acute extremity or laryngeal dysesthesias, fatigue, mild nausea and a cumulative sensory neuropathy were the common side effects
The toxicities were minimal
Total plasma platinum clearance was positively related with CrCl
Platinum clearance was associated with renal function
The overall toxicity of oxaliplatin appeared to be minimal
No dose reduciton is required for patients with mild to miderate renal insufficiency
Dose-limiting toxicity of oxaliplatin is neurotoxicity, which is difficult to assess and may depend on the duration of use
Long-term neurotoxicity needs to be studied and could be increased in patients with renal insufficiency
Feb 4, 2014 - For patients with renal cell carcinoma, expressive writing may improve cancer-related symptoms and physical functioning, according to a study published online Jan. 27 in the Journal of Clinical Oncology.